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Objective. Mycobacterium tuberculosis infection is a major global threat to human health. The only tuberculosis (TB) vaccine
currently available is bacillus Calmette-Gue´rin (BCG), although it has no efficacy in adults. Therefore, the development of a novel
vaccine against TB for adults is desired. Method. A novel TB vaccine expressing mycobacterial heat shock protein 65 (HSP65) and
interleukin-12 (IL-12) delivered by the hemagglutinating virus of Japan- (HVJ)- envelope was evaluated against TB infection
in mice. Bacterial load reductions and histopathological assessments were used to determine efficacy. Results. Vaccination by
BCG prime with IgHSP65+murine IL-12/HVJ-envelope boost resulted in significant protective efficacy (>10, 000-fold versus BCG
alone) against TB infection in the lungs of mice. In addition to bacterial loads, significant protective efficacy was demonstrated
by histopathological analysis of the lungs. Furthermore, the vaccine increased the number of T cells secreting IFN-γ. Conclusion.
This vaccine showed extremely significant protection against TB in a mouse model, consistent with results from a similar paper
on cynomolgus monkeys. The results suggest that further development of the vaccine for eventual testing in clinical trials may be
warranted.
1. Introduction
Tuberculosis (TB) is a major global threat to human
health, with about 2 million people dying every year from
Mycobacterium tuberculosis infection. The only TB vaccine
currently available is an attenuated strain of Mycobacterium
bovis, bacillus Calmette-Guerin (BCG), although its efficacy
against adult TB disease is unclear. Furthermore, multidrug-
resistant TB (MDR-TB) and extremely drug-resistant TB
(XDR-TB) are becoming big problems worldwide. For these
reasons, a prophylactic and therapeutic vaccine against TB
is sought. TB vaccines are classified into 4 main groups:
(1) DNA vaccines, (2) recombinant BCG vaccines, (3)
subunit vaccines, and (4) attenuated vaccines.
It is well established that protective immunity to
M. tuberculosis depends on both CD4+ and CD8+ T cells
[1–6]. DNA vaccines induce cellular immune responses,
including the Th-1-type cellular immune response, and
they prevent infections in animal models [7, 8]. In fact,
several human clinical trials have recently been initiated
to test the efficacy of DNA vaccines against emerging and
re-emerging infectious diseases including hepatitis B [9],
malaria [10–12], and HIV infections [13]. DNA vaccines
have also shown their potential as TB vaccines in mouse
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models [14–17]. However, in a guinea pig model, which is
one of the most biologically relevant systems available for
studying human pulmonary TB, DNA vaccines have not
been proven more efficacious than BCG [18]. The efficacy of
any experimental TB vaccine must be evaluated in human
clinical trials, and a vaccine against TB is still anxiously
awaited.
We have been developing a novel TB vaccine that
is a DNA vaccine expressing mycobacterial heat shock
protein 65 (HSP65) and interleukin-12 (IL-12), delivered by
the hemagglutinating virus of Japan- (HVJ)- liposome or
-envelope (HVJ-E) (HSP65 + IL-12/HVJ) [19–22]. The
former vaccine was 100-fold more efficacious than BCG
in a murine model on the basis of the elimination of M.
tuberculosis [19]. In the present study, we demonstrated that
the combination of BCG prime with HSP65 + IL-12/HVJ-
E vaccine-boost was 10,000-fold more efficacious than BCG
alone in a murine TB prophylactic model.
2. Materials and Methods
2.1. Bacteria. M. tuberculosis strains H37Rv and M. bovis
BCG Tokyo, were kindly provided by Dr. I. Sugawara
(JATA, Tokyo, Japan). M. bovis BCG Tokyo was maintained
in synthetic Sauton’s medium (Wako Chemicals, Osaka,
Japan). For the mouse infection studies, a single colony
of M. tuberculosis H37Rv was grown in Middlebrook 7H9
medium (DIFCO Laboratories, Detroit, MI; lot 137971
XA MD) supplemented with albumin-dextrose complex
and grown at 37◦C until approximately midlog phase.
Aliquots were stored at −80◦C and thawed 10 days before
use. Each bacterium was grown to midlog phase in 7H9
medium.
2.2. Animals. Inbred and specific pathogen-free female
BALB/c mice were purchased from Japan SLC (Shizuoka,
Japan). Mice were maintained in isolator cages, manipulated
in laminar flow hoods, and used between 8 and 10 weeks
of age. All animal experiments were approved by the
National Hospital Organization Kinki-chuo Chest Medical
Center Animal Care and Use Committee. All vaccinations
and experiments on isolated tissues were performed on
anesthetized animals with sevoflurane. Infected animals were
housed in individual microisolator cages in Biosafety Level
(BL) 3 animal facility of the NHO Kinki-chuo Chest Medical
Center.
2.3. Plasmid Construction. The HSP65 gene was amplified
from M. tuberculosis H37Rv genomic DNA, and cloned
into pcDNA3.1 (+) (Invitrogen, San Diego, CA) to generate
pcDNA-hsp65 (designated as HSP65 DNA) as described
previously [19]. The hsp65 gene was fused with mouse Igκ
secretion signal sequence, and pcDNA-Ighsp65 (designated
as IgHSP65 DNA) was generated. For construction of the
mouse IL-12 (mIL-12) p40 and p35 single-chain genes,
mIL12p35 and mIL12p40 genes were cloned from pcDNA-
p40p35 [21], fused and cloned into pcDNA3.1 (+) to
generate pcDNA-mIL12p40p35-F (designated as mIL-12
DNA).
2.4. HVJ-E Vaccination. HVJ-E was prepared as described
previously (Figure 1) [19–23]. The HVJ-E complex was
aliquoted and stored at −70◦C until use. Groups of BALB/c
mice were vaccinated 3 times at 3-week intervals with 100μL
of HVJ-E solution containing 50 μg of pcDNA-IgHSP65 and
50 μg of mIL12 DNA. These DNA vaccines were injected
into both anterior muscles in the tibia. Mice were vaccinated
using 1 × 106 colony-forming units (CFU) M. bovis BCG
Tokyo by subcutaneous injection at 4 different sites (left-
upper, right-upper, left-lower, and right-lower back). HVJ-E
DNA vaccine containing pcDNA-IgHSP65 and -mIL12 DNA
was designated as IgHSP65 + mIL-12/HVJ-E in this text.
2.5. Challenge Infection of Vaccinated Animals and Bac-
terial Load Determination. Mice were challenged by the
intravenous route with 5 × 105 CFU of M. tuberculosis
H37Rv 4 weeks after the third vaccination as described
previously (Figure 2) [19, 24]. 0.2mL of saline containing
5 × 105 CFU of H37Rv Mycobacterium tuberculosis were
injected into tail vein of mice. At 5 and 10 weeks after
M. tuberculosis H37Rv challenge, lungs, spleens, and livers
were aseptically homogenized by using a homogenizer in
saline, and serial dilutions of the organ homogenates were
plated on 7H11 Middlebrook agar (Kyokuto. Tokyo, Japan).
Plates were sealed and incubated at 37◦C, and the number of
colonies was counted 2 weeks later. Results were converted to
log10 values. The log10 [mean ± standard deviation (S.D.)]
values for CFU/organs/animals were calculated for each
experimental group. Weight of lungs, liver, or spleen was
measured by a balance (Sartorius Co. LP620S).
2.6. Histological Analysis. The lungs obtained from the mice
were fixed with 10% buffered formalin and embedded in
paraffin. Each block was sliced into 4-μm-thick sections
and stained using hematoxylin and eosin. Semiquantitative
morphometric analysis of pathological slides was performed
by amethodmodified over that of Dascher et al. (2003) using
a micrometer-attached microscope (Microphot-FXA, Nikon,
Japan) [19, 25, 26]. The longer axis and minor axis of each
granuloma in the field (×40 magnification) were measured
and then multiplied and summed. Three random fields from
each tissue section of mice were evaluated. The average
score of the fields was designated as the granuloma index
(×10−2 mm2). This method for the evaluation of granuloma
area was significantly correlated with the granuloma area
determined by a hematoxylin and eosin section scanning
method.
2.7. ELISPOT Assay. The spleens were removed aseptically
from vaccinated mice 3 weeks after the third vaccina-
tion. Antigen-specific IFN-γ-producing cells were deter-
mined by enzyme-linked immunosorbent spot (ELISPOT)
as described previously [19]. Briefly, ELISPOT plates (Mul-
tiScreen IP Filtration plate MAIPS45; Millipore, Bedford,
MA) were coated with antimouse IFN-γ MAb R4-6A2
(BD Biosciences Pharmingen. San Diego, CA). Spleen cells
from vaccinated mice were suspended at 1 × 107 cells/mL
(1 × 106 cells/well). The cells were placed into 6 antibody-
coated wells, and rHSP65 protein (10 μg/mL) or PPD
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Figure 1: Hemagglutinating virus of Japan- (HVJ)- envelope vaccination: pcDNA3.1/HSP65DNA + IL-12DNA were incorporated into an
HVJ-envelope empty vector (nonviral vector). Graphical representations of the HVJ-envelope empty vector in the presence or absence of
DNA are shown. Electronic microscopy (EM) photographs of the HVJ-envelope empty vector are also shown.
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Figure 2: Groups of mice were vaccinated 3 times every 3 weeks using the prime-boost method and challenged intravenously with M.
tuberculosis H37Rv as described in the Materials andMethods section. Five or 10 weeks after challenge with TB, protection was measured by
enumerating bacterial loads (CFU) in the lungs, liver, and spleen of the vaccinated mice.
(10 μg/mL) was added to each well. After 20 h of incubation
at 37◦C, cells were removed by washing the plates, and
the site of cytokine secretions was detected using biotiny-
lated antimouse IFN-γ MAb XMG1.2 (BD Biosciences
Pharmingen) and streptavidin-alkaline phosphatase conju-
gate (BDBiosciences Pharmingen). The enzyme reaction was
developed with BCIP-NBT substrate (Vector Laboratories
Inc., Burlingame, CA). Spot-forming cells (SFCs) were
enumerated using the KS ELISPOT system (Carl Zeiss,
Hallbergmoos, Germany).
2.8. Statistical Analysis. Dunnett’s tests (multiple compar-
isons) were used to compare log10 values of CFUs between
groups following challenge and used to compare T-cell
responses between groups in the ELISPOT assay. A P-value
of < .05 was considered significant.
3. Results and Discussion
3.1. Results
3.1.1. Prophylactic Efficacy Using Prime-Boost Method. The
IgHSP65 + mIL-12/HVJ-E and BCG vaccines were admin-
istered using the prime-boost method as shown in Table 1.
At 5 and 10 weeks after intravenous challenge of
M. tuberculosis H37Rv, the number of CFUs in the lungs,
spleen, and liver were determined. Figure 3(a) shows the
result of bacterial loads 5 weeks after challenge.
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Table 1: BCG-HVJ-E/HSP65 DNA + IL-12 DNA Prime/Boost
Experiment. Groups of mice were vaccinated 2 or 3 times with
IgHSP65 +mIL-12/HVJ-E vaccine and/or BCG by using the prime-
boost method. IgHSP65 + mIL-12/HVJ-E vaccine was injected
intramuscularly, and BCG was injected subcutaneously. 4 weeks
after the last immunization, M. tuberculosis H37Rv was challenged
intravenously. 5 weeks and 10 weeks after TB challenge, protection
was measured by enumerating bacterial loads (CFU) in the lungs,
liver, and spleen from vaccinated mice. One week before the TB
challenge, the immune responses of cytotoxic T cells, proliferation
of T cells, and cytokines (IFN-γ, IL-2, IL-6) production were
assayed.
Group
First
immunization
Second
immunization
Third
immunization
1 — — —
2 — — BCG
3
HSP65 +
IL-12/HVJ-E
HSP65 +
IL-12/HVJ-E
HSP65 +
IL-12/HVJ-E
4 BCG
HSP65 +
IL-12/HVJ-E
HSP65 +
IL-12/HVJ-E
5
HSP65 +
IL-12/HVJ-E
HSP65 +
IL-12/HVJ-E
BCG
13 mice per group.
3 mice for the in vitro assay prior to challenge (IFN-γ ELISPOT, etc.).
10 mice for the protection study (half of the mice were used for necropsy at
5 weeks after challenge and half at 10 weeks).
Vaccination by BCG prime + IgHSP65 + mIL-12/HVJ-E
boost showed significant protective effects on the bacterial
loads in the lungs as compared to BCG alone (P < .01).
The prime-boost method using DNA and BCG vaccines
showed extremely strong protective efficacy (>10,000-fold
versus BCG alone) regardless of the order of administration
(Figure 3(a)). Vaccination with BCG vaccine alone decreased
TB CFUs in the lungs by 1 log unit as compared to
nonvaccinated mice.
Vaccination with IgHSP65 + mIL-12/HVJ-E and BCG by
the prime-boost method also showed significant protective
efficacy on the bacterial loads in the liver as compared to
BCG (>100-fold, P < .05; Figure 3(b)). The combination of 2
vaccines and administration by the prime-boost method also
exerted a significant protective effect on the bacterial load
in the spleen as compared to naive control group (10-fold
higher, P < .05; Figure 3(c)).
Body weight of vaccinated mice was similar in all
vaccinated groups. Tissue weights of spleens and livers in the
prime-boost groups were lower than those of naive group
(Figures 4 and 5).
We also confirmed the greater enhancement of protective
effects in the BCG-DNA vaccine combination groups than
those in the naive control group or BCG-alone group 10
weeks after challenge (data not shown). These results indicate
that treatment using 2 vaccines by the prime-boost method
was more effective than BCG alone.
3.1.2. Histological Analysis. In addition to the reduction of
bacterial loads, the efficacies of each vaccine were assessed by
histological analysis. The number and size of granulomatous
lesions in the lungs were significantly lower and smaller,
respectively, in the mice vaccinated by the BCG prime-
DNA boost group than in the naive control mice and BCG
control mice groups (Figure 6). Quantitative evaluation of
the granulomatous lesions clearly showed that the BCG
prime with IgHSP65 + mIL-12/HVJ-E boost significantly
reduced the granuloma index in the lungs as compared to
naive and BCG groups (P < .05; Figure 7). Thus, vaccination
by the prime-boost method has the capability to reduce
pulmonary lesions caused by M. tuberculosis infection.
3.1.3. Immunological Analysis. Furthermore, BCG prime
with IgHSP65 + mIL-12/HVJ-E boost augmented the pro-
liferation and IFN-γ production of HSP65 antigen-specific T
cells in the K-S ELISPOT Assay. The efficacy of BCG prime
with IgHSP65 + mIL-12/HVJ-E boost was higher compared
with BCG Tokyo alone or IgHSP65 + mIL-12/HVJ-E prime
with BCG boost (Figure 8).
These data indicate that the protective efficacies of BCG
prime with IgHSP65 + mIL-12/HVJ-E boost are strongly
associated with the number and activity of IFN-γ-secreting
and HSP65-specific T cells. Taken together, combinational
vaccination with BCG and IgHSP65 + mIL-12/HVJ-E by
the prime-boost method is capable of augmenting T-cell
activation. In addition, increase of IFN-γ-secreting cells is
involved in the reduction of bacterial burden and lesions
in the lungs. The efficacies of the prime-boost method are
greater than those achieved by vaccination with BCG alone.
3.2. Discussion. In this study, we evaluated the protective effi-
cacy of IgHSP65 + mIL-12/HVJ-E vaccine, using the prime-
boost method. One of the significant findings was that the
combination of IgHSP65 + mIL-12/HVJ-E and BCG led to
a remarkably high degree of protection against intravenous
challenge infection with virulent M. tuberculosis; bacterial
numbers exponentially declined in 3 organs, especially in the
lungs (10,000-fold lower than that of mice vaccinated with
BCG alone; Figure 3(a)).
The pathological parameters of protection included
reductions in the mean lung granulomatous lesion score in
our study. The protective efficacies of BCG with IgHSP65
+ mIL-12/HVJ-E administered by the prime-boost method
were indicated on the basis of histopathological methods
as well as bacterial loads. Histopathological analysis showed
that mice vaccinated with BCG prime with IgHSP65 + mIL-
12/HVJ-E boost had fewer and smaller lesions in the lungs
and significantly less lung granuloma than naive mice and
mice treated with BCG alone. These results suggest that
severe toxicities (Koch phenomenon) were suppressed by the
combination of two kinds of vaccines.
The data in the present study also show that the protec-
tive efficacy of BCG prime with IgHSP65 + mIL-12/HVJ-
E boost is strongly associated with the emergence of IFN-
γ-secreting T cells upon stimulation with HSP65. In the
previous study, we demonstrated that in vivo function of
CD8-positive T cells as well as CD4-positive T cells is
involved in prophylactic efficacy of the IgHSP65 + mIL-
12/HVJ-E in mice [22].
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Figure 3: (a) Mouse protection studies using the prime-boost method. Groups of mice vaccinated with HVJ-envelope (HVJ-E) DNA
and/or BCG were challenged by intravenous injection with M. tuberculosis H37Rv. Five weeks after challenge, protection was measured
by enumerating the bacterial loads (CFU) in the lungs. Results are expressed as the mean log10 ± S.D. of CFU. The statistical significance of
differences between individual groups in the CFU number was determined by Dunnett test (n = 5); ∗P < .01 and ∗∗P < .05; the statistical
significance of differences (P < .01) of the G1 (naive) group compared to the G3 group (DNA/DNA/DNA), G4 group (BCG/DNA/DNA), or
the G5 group (DNA/DNA/BCG). The statistical significance of differences (∗∗P < .05) of the G2 group (BCG-alone group) compared to the
G3 group (DNA/DNA/DNA), that of differences (P < .01) of the G2 group compared to the G4 group (BCG/DNA/DNA), or the G5 group
(DNA/DNA/BCG). (b) Mouse protection studies using the prime-boost method. Groups of mice vaccinated with HVJ-E DNA and/or BCG
were challenged by intravenous injection with M. tuberculosis H37Rv. Five weeks after challenge, protection was measured by enumerating
the bacterial loads (CFU) in the liver. Results are expressed as the mean log10 ± S.D. of CFU. The statistical significance of differences between
individual groups in the CFU number was determined by Dunnett test (n = 5), ∗P < .01; the statistical significance of differences (P < .01)
of the G1 (naive) group compared to the G4 group (BCG/DNA/DNA), or the G5 group (DNA/DNA/BCG). The statistical significance of
differences (P < .05) of the G2 group (BCG-alone group) compared to the G4 group (BCG/DNA/DNA). The statistical significance of
differences(P < .01) of the G2 group compared to the G5 group (DNA/DNA/BCG). The statistical significance of differences (P < .05) of the
G3 group (DNA/DNA/DNA) compared to G4 (BCG/DNA/DNA). That of differences (P < .01) of the G3 group compared to the G5 group.
(c) Mouse protection studies using the prime-boost method. Groups of mice vaccinated with HVJ-E DNA and/or BCG were challenged by
intravenous injection with M. tuberculosis H37Rv. Five weeks after challenge, protection was measured by enumerating the bacterial loads
(CFU) in the spleen. Results are expressed as the mean log10 ± S.D. of CFU. The statistical significance of differences between individual
groups in the number of CFU was determined by Dunnett test (n = 5); ∗∗P < .05; the statistical significance of differences (P < .05) of the
G1 (naive) group compared to the G4 group (BCG/DNA/DNA).
In this study, we used the murine model of TB, which
may not reflect the pathologic status of human TB. As to
the difference of the infection route, our previous results
in a guinea pig model used in a collaborative study with
Dr. D. McMurray (Texas A&M University) showed that
vaccination with HSP65 + guinea pig IL-12/HVJ resulted
in better protection against pulmonary pathology caused by
aerosol challenge with M. tuberculosis than BCG vaccination
(data not shown).
In addition, we have recently confirmed that the prime-
boost method was also effective in a cynomolgus monkey
model [20–22]. We evaluated our HSP65 + human IL-
12/HVJ (HSP65 + hIL-12/HVJ) in the monkey model
infected by an intratracheal instillation (aerogenic route),
which is currently the best animal model of human TB.
Vaccination with HSP65 + hIL-12/HVJ resulted in better
protective efficacy than that with BCG alone on the basis of
the erythrocyte sedimentation rate test, chest X-ray findings,
and immune responses. In addition, vaccination with HSP65
+ hIL-12/HVJ resulted in increased survival for over a year.
This was the first report of successful DNA vaccination
against M. tuberculosis in a monkey model [21].
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Figure 4: Tissue weight in mouse protection studies using the
prime-boost method. Groups of mice vaccinated with HVJ-E DNA
and/or BCG were challenged by intravenous injection with M.
tuberculosis H37Rv. Five weeks after challenge, spleen weight was
measured. Results are expressed as the mean ± S.D. in grams
(g). The statistical significance of differences between individual
groups in the weight was determined by Dunnett test (n = 5),
∗P ≤ .01; the statistical significance of differences (P < .01) of the
G1 (naive) group compared to the G2 group (BCG-alone group),
G3 group (DNA/DNA/DNA), G4 group (BCG/DNA/DNA), or G5
group (DNA/DNA/BCG).
Most importantly, protective efficacy was augmented
when BCG and HSP65 + hIL-12/HVJ were administered by
the prime-boost method. Survival rates of BCG alone, saline
control, HSP65 + hIL-12/HVJ-prime with BCG-boost, and
BCG-prime with HSP65 + hIL-12/HVJ-boost groups were
33%(2/6), 50%(3/6), 50%(2/4), and 100%(4/4) at 12 months
after the infection (aerogenic route), respectively [21]. We
also evaluated immune responses in the monkey model of
TB. Antigen-specific IFN-γ-production and proliferation of
peripheral blood lymphocyte (PBL) were enhanced by the
vaccination using the prime-boost method.
We also demonstrated efficacies in the monkey model
when the boost was performed after a long-term period (4
months) from the prime. The prolongation of the survival
was observed in the BCG-prime and HSP65 + IL-12/HVJ-
booster group [27]. Improvement of ESR, increase of the
body weight and augmentation of IFN-γ production, and
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Figure 5: Tissue weight in mouse protection studies using the
prime-boost method. Groups of mice vaccinated with HVJ-E DNA
and/or BCG were challenged by intravenous injection with M.
tuberculosis H37Rv. Five weeks after challenge, liver weight was
measured. Results are expressed as the mean ± S.D. in grams (g).
The statistical significance of differences between individual groups
in the weight was determined by Dunnett test (n = 5), ∗P < .01;
the statistical significance of differences (P ≤ .01) of the G1 (naive)
group compared to the G3 group (DNA/DNA/DNA), G4 group
(BCG/DNA/DNA), or G5 group (DNA/DNA/BCG). ∗∗P < .05; that
of differences (P < .05) of the G1 group compared to the G2 group
(BCG alone group).
proliferation of PBL were also observed in the BCG-prime
and HSP65 + IL-12/HVJ-booster group.
Taken together, these results clearly demonstrated that
BCG-prime with HSP65 + hIL-12/HVJ-boost could provide
extremely strong protective efficacy against M. tuberculosis
in a cynomolgus monkey model (intratracheal infection
route), which is currently the best animal model of human
TB [21].
The prime-boost method was reported in a study of
the MVA85A vaccine, which is a modified vaccinia virus
Ankara (MVA) strain expressing antigen 85A. In phase I
studies in humans, this vaccine has induced high immune
responses in previously BCG-vaccinated individuals [28].
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Figure 6: Histopathological analysis of vaccinated mice 5 weeks after M. tuberculosis challenge. Representative photomicrographs of
lung tissue sections harvested from the G1 naive control group, G2 (BCG alone) group, G3 group (DNA/DNA/DNA), and G4 group
(BCG/DNA/DNA) are shown (5 weeks after M. tuberculosis challenge, hematoxylin and eosin staining, × 4 objective). There was much
infiltration of mononuclear cells and extensive parenchymal destruction by large, poorly demarcated granuloma in the lungs from the G1
(naive control) group and G2 (BCG alone) group. In the G3 (DNA/DNA/DNA) group and G4 (BCG/DNA/DNA) group, there was less
inflammation, and only a few granulomas were observed.
Boosting BCG vaccination with MVA85A downregulates the
immunoregulatory cytokine TGF-β1 [29]. Aeras-402 DNA
(DNA that expressed 85A, 85B, and TB10.4) vaccine using
adenovirus vector is intended for use as a boosting vaccine
in BCG-primed individuals [30]. Several vaccines have been
used with a prime-boost strategy to complement immune
responses [31].
DNA vaccines are a relatively new approach to induce
immunities for the protection of infectious diseases [14, 19,
22, 32–34]. Prophylactic and therapeutic DNA vaccines were
established by using several kinds of vectors such as HVJ-
liposome, HVJ-E, adenovirus vector, adenoassociated virus
vector, and lentivirus vector [19–22, 35, 36]. In order to
explore the preclinical use of a tuberculosis DNA vaccine
combination of IL-12 DNA with hsp65 DNA, we chose
the HVJ-based delivery system (HVJ-liposome and HVJ-
E). These systems have high transfection efficiency and are
available for repeated in vivo gene transfection without
reduction of gene transfer efficiency or apparent toxicity.
These characters of HVJ-liposomes support the feasibility of
its clinical application not only for cancer gene therapy but
also for DNA vaccinations. In a recent study, highly efficient
gene expression in muscle cells was observed for several
weeks when pcDNA3 plasmid containing the human tumor
antigen genes, MAGE-1 and MAGE-3, were encapsulated
in HVJ-liposomes and injected intramuscularly in mice
[37]. Effective induction of CD4+ T-cell responses by a
hepatitis B core particle-based HIV vaccine was achieved
by subcutaneous administration of HVJ-liposomes in mice
[38]. HVJ-liposomes were also very effective as a mucosal
vaccine against HIV infection [39]. Thus, it is likely that
HVJ proteins may be responsible for the induction of a
robust immune response. No side effects were observed when
repetitive injections of HVJ-liposomes were performed in
mice, rats, or monkeys. We have previously developed an
HVJ-E using inactivated Sendai virus, as a nonviral vector
for drug delivery [40–42]. It can be used for efficient delivery
of DNAs, siRNAs, proteins, and anticancer drugs into cells
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Figure 7: Granuloma index of the G1, G2, G3, G4, and G5 (DNA/DNA/BCG) groups in the lungs 5 weeks and 10 weeks after M. tuberculosis
challenge. Results are expressed as the mean ± S.D. of triplicates of 5 mice per group. The statistical significance of differences between the
groups was determined by Dunnett test, P < .01 as compared with the naive (N) group or the BCG alone (B) group. P < .05 as compared
with the BCG alone (B∗) group. The statistical significance of differences (P < .05) of granuloma index of 5 weeks G3 group compared to
the G4 group.
both in vitro and in vivo [40, 43, 44]. Therefore, HVJ-E was
used as an efficient and safe vector for DNA vaccine against
TB in the present study.
Mycobacterial heat shock protein 65 (HSP65) is a poten-
tial target for protective immunity and has been studied
extensively [19]. Several studies have reported that hsp65
DNA vaccines can strongly induce protective immune
responses in mice against virulent M. tuberculosis infections
[20–22]. Protection is attributed to the establishment of
a cellular immune response dominated by HSP65-specific T
cells which produce IFN-γ and are cytotoxic towards infected
cells. Furthermore, Lowrie and colleagues have reported that
this vaccine reduces bacterial loads in mice infected with M.
tuberculosis when given therapeutically after infection [32].
One of the major roles of IL-12 is the induction of IFN-γ-
mediated immune responses tomicrobial pathogens. Cooper
and colleagues have demonstrated the importance of IL-12
in generation of the protective response to tuberculosis [45].
Coadministration of the IL-12 gene, which induces an IFN-
γ-mediated immune response to microbial pathogens, with
various tuberculosis DNA vaccines including hsp65 DNA
[46], and 35KMW DNA [47], may boost the efficacy of
these DNA vaccines to the levels achieved with BCG in the
mouse model, although an inhibitory effect rather than a
synergistic effect on immunotherapy was observed in mice
coadministered hsp65 DNA vaccine plus the IL-12 gene [32].
In conclusion, we have shown efficacy of a novel HVJ-E
DNA vaccine encapsulating HSP65 DNA with IL-12 DNA in
the mouse model of TB. These results suggest that HSP65
+ IL-12/HVJ could be a promising candidate for a new
tuberculosis vaccine superior to BCG. To this aim, protective
efficacy and immune responses were further studied in
nonhuman primates before proceeding to human clinical
trials.
In Japan and other countries, BCG is inoculated into
human infants up to 6 months after birth. Therefore, BCG
prime in infants and HSP65 + hIL-12/HVJ boost in adults
(including junior high school students, high school students,
and the elderly) may be required for significant improvement
of clinical protective efficacy against TB. Thus, our results
with the HSP65 + hIL-12/HVJ vaccine in a murine prophy-
lactic model and cynomolgus monkey prophylactic model
provide a significant rationale for moving this vaccine into
clinical trials. Indeed, multiple animal models are available
to accumulate essential data on the HVJ-E DNA vaccine in
anticipation of a phase I clinical trial.
4. Conclusions
Vaccination by BCG prime with a novel vaccine (IgHSP65
+ mIL-12/HVJ-E) boost resulted in significant protective
efficacy (10,000-fold greater than BCG alone) against TB
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Figure 8: ELISPOT assay for IFN-γ antigen-specific responses
in the spleens of vaccinated mice following stimulation with
rHSP65 protein. Spleen cell cultures were stimulated with rHSP65
protein for 20 h. The numbers of IFN-γ-secreting cells specific for
rHSP65 protein per million cells were determined individually by
ELISPOT assay. Results are expressed as the mean ± S.D. of 6
wells of 3 mice per group. The statistical significance of differences
between individual groups in the number of IFN-γ-secreting cells
was determined by Dunnett test. The statistical significance of
differences (P < .01) of the G1 (naive) group compared to the G2
(BCG alone group), G3 (DNA/DNA/DNA), G4 (BCG/DNA/DNA),
or G5 (DNA/DNA/BCG). The statistical significance of the G2
group difference (P < .01) compared to the G4 or the G5. The
statistical significance of the G3 group differences (P < .01)
compared to the G4. P < .01; the G4 group compared to the G5.
The statistical significance of the G3 group differences (P < .05)
compared to the G5.
infection in the lungs of mice. In addition to bacterial
loads, significant protective immunity was demonstrated by
histopathological analysis of the lungs. This vaccine showed
extremely significant protection against TB, suggesting that
further development for eventual testing in clinical trials may
be warranted.
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